Jul 26, 2024 8:35am EDT ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
Jul 26, 2024 8:30am EDT ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
May 14, 2024 4:01pm EDT ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Apr 30, 2024 7:00am EDT ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Apr 09, 2024 7:00am EDT ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Apr 01, 2024 4:15pm EDT ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Jan 22, 2024 7:00am EST ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine